Radiation and Peptide Therapy for Large Gut Neuroendocrine Tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial combines external radiation with a targeted radioactive drug (PRRT) to treat large, slow-growing neuroendocrine tumors in the gut that have spread and are not removable by surgery. It aims to see if this combination works better than either treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a neuroendocrine tumor that is slow-growing (grade 1 or 2) and cannot be removed by surgery.
- Your tumor has gotten worse after 1 or 2 prior treatments.
- You have at least one tumor that is 3 cm or larger on a CT or MRI scan.
- Your tumor shows up on a special PET scan called DOTATATE, meaning it has somatostatin receptors.
- Your kidney and liver function, as well as blood counts, are within acceptable levels before starting.
- You have not had radiation to the same area before, including PRRT or Y-90 radioembolization.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Hear when a new Digestive System Neuroendocrine Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.